Floatz logo

Sitravatinib

Pembrolizumab

Sarah GoldbergSmall moleculePhase 2Active
CCC
49/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
34/ 100
Competitive Position
89/ 100

Competitive context

5 Active assets in the Pembrolizumab cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Ismail Gögenur
Phase 2B
LENVATINIB
National Taiwan University Hospital
Phase 2B
Cyclophosphamide
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2CCC
Mirabegron
Obstetrics & Gynecology Hospital of Fudan University
Phase 2CCC
Epirubicin
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2CCC

Same molecule, other indications

Sitravatinib is also rated in:

nonpapillary renal cell carcinomaDormant
B
Indicative ·
57 / 100
View asset →
renal cell carcinomaDormant
CCC
Indicative ·
55 / 100
View asset →
metastatic malignant neoplasmDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →